The bryostatins are a family of marine natural products that display a wide range of biological activities, most notably their anticancer activity in vivo. 1 This effect is attributed to their ability to modulate the functions of protein kinase C isozymes within cells. One of the members of this family, bryostatin 1, is currently in several phase I and phase II clinical trials for the treatment of several cancers. 2 The syntheses of bryostatins and their analogues have been an active research area since the structure elucidation of bryostatin 1 in 1982. 3 To date, three total and one formal syntheses have been reported, 4-7 and potent bryostatin analogues 8 have been identified. In the analogue synthesis front, efforts have been centered on the simplification of the 26-membered macrolactone backbone. Herein, we report the synthesis of a ring-expanded analogue 1 (Scheme 1), which retains all the functionalities in the bryostatins, and their biological activities against several cancer cell lines.
The bryostatins are a family of marine natural products that display a wide range of biological activities, most notably their anticancer activity in vivo. 1 This effect is attributed to their ability to modulate the functions of protein kinase C isozymes within cells. One of the members of this family, bryostatin 1, is currently in several phase I and phase II clinical trials for the treatment of several cancers. 2 The syntheses of bryostatins and their analogues have been an active research area since the structure elucidation of bryostatin 1 in 1982. 3 To date, three total and one formal syntheses have been reported, [4] [5] [6] [7] and potent bryostatin analogues 8 have been identified. In the analogue synthesis front, efforts have been centered on the simplification of the 26-membered macrolactone backbone. Herein, we report the synthesis of a ring-expanded analogue 1 (Scheme 1), which retains all the functionalities in the bryostatins, and their biological activities against several cancer cell lines.
Shown in Scheme 1 is our retrosynthetic analysis. Inspired by the B-ring and C-ring segments, we developed a Ru-catalyzed tandem process 9 for the synthesis of 4-methylene-cis-2,6-tetrahydropyran and a Pd(II)-catalyzed tandem reaction 10 for the synthesis of dihydropyrans. Since our Pd(II) catalysis necessitates an early installation of the sensitive R, -unsaturated methyl ester at C(13), we decided to evaluate a ring-closing metathesis (RCM) approach for the formation of the macrocycle. 11, 12 The steric hindrance of the C(16)-C(17) double bond (bryostatin numbering) made this approach risky, but we were encouraged by the potential to access ring-expanded analogues. 13 Our synthesis of the northern hemisphere 2 is outlined in Scheme 2. The alcohol 9 14 was converted to the hydroxyketone 12 following a procedure 5 from Evans. Subsequent hydroxyl-directed antireduction, 15 lactonization, 16 and protection gave lactone 14. At this stage, a ,γ-unsaturated ketone was introduced to give 5. The key Ru-catalyzed tandem coupling between enone 5 and homopropargylic alcohol 4 furnished tetrahydropyran 15 in 56% yield as a 9:1 cis:trans diastereomeric mixture, and no double bond isomer was observed. Although excess 5 (2.2 equiv) was used in the reaction, 1.2 equiv was recovered and recycled. Subsequent bromination and deprotection gave the corresponding diol, which was subjected to a tandem lactone methanolysis-ketalization to afford 16. Compound 16 was converted to vinyl bromide 16 and then the northern hemisphere 2 in eight steps.
Our synthesis of the southern hemisphere 3 commenced with D-glactonic acid 1,4-lactone (Scheme 3). Epoxide opening of 18 17 with methyl propionate delivered methyl ynoate 19, which was coupled with alkyne 20 18 under our tandem Pd(II) catalysis conditions to give dihydropyran 21 in 55% yield. 19 At this stage, the vicinal oxygens at C(19) and C (20) were introduced via an epoxidation. Unfortunately, the stereochemistry of the newly introduced C(20) hydroxyl group was the opposite of that required for our synthesis. This undesired selectivity was overcome by a Dess-Martin oxidation 20 /Luche reduction 21 sequence. After intro- ducing a terminal olefin via a Takai olefination 22 and a Negishi cross-coupling, 23 the resulting triene 24 was hydrolyzed and monosilylated to give the southern hemisphere 3, which was then coupled with 2 in the presence of 2-methyl-6-nitrobenzoic acid anhydride 24 to give 25. Gratifyingly, treatment of 25 with GrubbsHoveyda catalyst 25 gave 31-membered lactone 26 as an inseparable 1:1 E:Z mixture in 80% yield. 26 Final deprotection gave triols 1 and 27, which were separated by preparative TLC.
The compounds 1 and 27 were tested against several cancer cell lines. Particularly impressive and interesting is the ability of 1 to inhibit the growth of NCI-ADRsa breast cancer cell line with added multi-drug-resistant pumpsswith an IC 50 of 123 nM. 27 In summary, a ring-expanded bryostatin analogue 1 with potent antitumor activity against the NCI-ADR cancer cell line was synthesized. Notable features include a Ru-catalyzed tandem tetrahydropyran formation, a Pd-catalyzed tandem dihydropyran formation, and a ring-closing metathesis. The chemistry reported herein should be applicable to future syntheses of the bryostatins and their analogues.
